Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient

Exclusion Criteria Co-existing Condition: Patients with the following are excluded: * Cytomegalovirus (CMV) disease who meet the criteria for a treatment IND protocol, or other clinical studies, including controlled clinical studies of anticytomegalovirus therapy in peripheral CMV retinitis in patients with AIDS. * Mild to moderate CMV infections who fail to meet the severity criteria. CMV syndrome (i.e., cytopenia, increased liver enzymes, fever, viremia, viruria) is not considered immediately life-threatening. * Transplant patients in whom trial reduction of immunosuppressive drug treatment is feasible. * Children with congenital or neonatal CMV where there is not a documented primary or acquired immunodeficiency. * Hypersensitivity to acyclovir or ganciclovir. * Receiving antimetabolite treatment that cannot be discontinued. Concurrent Medication: Excluded: * Antimetabolites. * Alkylating agents. * Nucleoside analogs (topical ophthalmics are permitted). * Interferon. * Foscarnet. * Cytokines. Patients with the following are excluded: * Cytomegalovirus (CMV) infection who meet the criteria for a treatment IND protocol, or other clinical studies, including controlled clinical studies of anticytomegalovirus therapy in peripheral CMV retinitis in patients with AIDS. * Mild to moderate CMV infections who fail to meet the severity criteria. CMV syndrome (i.e., cytopenia, increased liver enzymes, fever, viremia, viruria) is not considered immediately life-threatening. * Transplant patients in whom trial reduction of immunosuppressive drug treatment is feasible. * Children with congenital or neonatal CMV where there is not a documented primary or acquired immunodeficiency. * Hypersensitivity to acyclovir or ganciclovir. * Receiving antimetabolite treatment that cannot be discontinued. Patients must qualify as follows: * Previously enrolled in compassionate use study (ICM 1257/1257A) or have terminated from another Syntex ganciclovir study. * Diagnosis of AIDS and life-threatening Cytomegalovirus (CMV) infection. * Diagnosis of other immunodeficiencies other than AIDS, with life-threatening or sight-threatening CMV disease.